Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY-1: KP104 in Healthy Subjects
NCT05490017Phase 1Completed
- Sponsor
- Kira Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KP104 in paroxysmal nocturnal hemoglobinuria (PNH) (12 arms), sponsored by Kira Pharmaceuticals. Primary endpoints: Treatment Emergent Adverse Events, Treatment Emergent Serious Adverse Events and 2 more. Started Dec 2020; status: completed.
02
Drugs
KP104
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05490017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490017.